Abstract
Capmatinib may be effective in patients with advanced non–small cell lung cancer who have MET exon 14 skipping mutations. In the phase II GEOMETRY mono-1 trial, the drug elicited high overall response rates and relatively durable responses in newly diagnosed and previously treated patients, including those with brain metastases.
©2020 American Association for Cancer Research.
2020
American Association for Cancer Research.
You do not currently have access to this content.